Maternal COVID-19 Vaccination May Reduce Neonatal Respiratory Distress
24 Jan 2024
VaccineClinical ResultmRNAImmunotherapyEmergency Use Authorization
WEDNESDAY, Jan. 24, 2024 -- Maternal COVID-19 vaccination is associated with reduced frequency of neonatal respiratory distress (RD), according to a study published online Jan. 24 in Nature Communications.
Olivia M. Man, from the David Geffen School of Medicine at the University of California in Los Angeles, and colleagues examined the association between maternal COVID-19 vaccination and neonatal RD using a longitudinal cohort of mother-infant pairs. The study included 221 mothers with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during pregnancy and 227 exposed fetuses.
The researchers found that SARS-CoV-2-exposed uninfected (SEU) infants had unusually high rates of RD (17 percent), with an odds ratio of 3.06 for RD in term neonates born to unvaccinated individuals compared with those born to individuals vaccinated before maternal infection. A robust inflammatory response associated with ciliary dysregulation and enhanced immunoglobulin E production was seen in a proteomic analysis among SEU infants with RD.
"Maternal vaccination against COVID-19 reduced maternal disease severity and the frequency of neonatal RD. Pregnant persons should be encouraged to receive mRNA COVID-19 vaccinesCOVID-19 vaccines, regardless of history of prior COVID-19 infection," the authors write. "More research is needed to understand the impact of maternal COVID-19 vaccination on long-term infant health and development, including chronic pulmonary conditions."
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
Further Support and Information on COVID-19
COVID-19: Prevention & Investigational Treatments
COVID-19 Support Group
Coronavirus Disease Guide
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.